- Home
- SF vs PCVX Comparison
SF vs PCVX Comparison
Compare SF & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SF
- PCVX
- Stock Information
- Founded
- SF 1890
- PCVX 2013
- Country
- SF United States
- PCVX United States
- Employees
- SF N/A
- PCVX N/A
- Industry
- SF Investment Bankers/Brokers/Service
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- SF Finance
- PCVX Health Care
- Exchange
- SF Nasdaq
- PCVX Nasdaq
- Market Cap
- SF 9.8B
- PCVX 4.0B
- IPO Year
- SF N/A
- PCVX 2020
- Fundamental
- Price
- SF $112.93
- PCVX $31.23
- Analyst Decision
- SF Buy
- PCVX Strong Buy
- Analyst Count
- SF 8
- PCVX 8
- Target Price
- SF $114.88
- PCVX $114.17
- AVG Volume (30 Days)
- SF 624.1K
- PCVX 1.5M
- Earning Date
- SF 10-22-2025
- PCVX 11-04-2025
- Dividend Yield
- SF 1.64%
- PCVX N/A
- EPS Growth
- SF 9.88
- PCVX N/A
- EPS
- SF 5.17
- PCVX N/A
- Revenue
- SF $5,091,577,000.00
- PCVX N/A
- Revenue This Year
- SF $10.70
- PCVX N/A
- Revenue Next Year
- SF $12.22
- PCVX N/A
- P/E Ratio
- SF $21.70
- PCVX N/A
- Revenue Growth
- SF 11.86
- PCVX N/A
- 52 Week Low
- SF $73.27
- PCVX $27.66
- 52 Week High
- SF $120.64
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- SF 48.62
- PCVX 50.95
- Support Level
- SF $111.63
- PCVX N/A
- Resistance Level
- SF $116.25
- PCVX $33.32
- Average True Range (ATR)
- SF 2.19
- PCVX 1.15
- MACD
- SF -0.30
- PCVX -1.07
- Stochastic Oscillator
- SF 24.25
- PCVX 92.75
About SF Stifel Financial Corporation
Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.